Neurimmune
UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance
UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships